Sign inCreate account

Report workspace tools

NCT04590248COMPLETEDanonymous

A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

Sponsor

Source record

AstraZeneca

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Adavosertib

Indication / condition

AI-normalized

Uterine Serous Carcinoma

Intervention

Source record

Adavosertib

Source & freshness

Source record

NCT ID

NCT04590248

Original source

ClinicalTrials.gov

Source last updated

Aug 14, 2023

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04590248

Title

A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

Sponsor

AstraZeneca

Status

COMPLETED

Phase

PHASE2

Condition raw

Uterine Serous Carcinoma

Condition normalized

Uterine Serous Carcinoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Adavosertib

Target normalized

Adavosertib

Interventions

Adavosertib

Public preview

Source record

This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04590248

Status

COMPLETED

Phase

PHASE2

Sponsor

AstraZeneca

Executive brief

Investment-Ready Snapshot

This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 14, 2023
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04590248

Indication

Uterine Serous Carcinoma

Modality

small molecule

Target

Adavosertib

Intervention

Adavosertib

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.